Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study

Introduction: Despite the emergence of atezolizumab and bevacizumab (A + B) as standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC), a comprehensive understanding of the clinical significance of immune-related adverse events (irAEs) remains limited. We aimed to assess...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Heechul Nam, Jaejun Lee, Ji Won Han, Soon Kyu Lee, Hyun Yang, Hae Lim Lee, Pil Soo Sung, Hee Yeon Kim, Seok-Hwan Kim, Myeong Jun Song, Jung-Hyun Kwon, Chang Wook Kim, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Karger Publishers 2023-12-01
coleção:	Liver Cancer
Assuntos:	hepatocellular carcinoma atezolizumab bevacizumab immune-related adverse events time-to-treatment discontinuation
Acesso em linha:	https://beta.karger.com/Article/FullText/535839
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!